Your browser is no longer supported. Please, upgrade your browser.
Settings
DMPI DelMar Pharmaceuticals, Inc. daily Stock Chart
DMPI [NASD]
DelMar Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.36 Insider Own0.60% Shs Outstand3.98M Perf Week-9.52%
Market Cap3.06M Forward P/E- EPS next Y- Insider Trans- Shs Float3.61M Perf Month-49.00%
Income-8.00M PEG- EPS next Q- Inst Own17.20% Short Float5.01% Perf Quarter-65.77%
Sales- P/S- EPS this Y26.40% Inst Trans- Short Ratio0.24 Perf Half Y-76.80%
Book/sh-1.94 P/B- EPS next Y- ROA-173.60% Target Price12.00 Perf Year-86.18%
Cash/sh0.55 P/C1.39 EPS next 5Y- ROE264.90% 52W Range0.71 - 8.50 Perf YTD-77.48%
Dividend- P/FCF- EPS past 5Y13.50% ROI- 52W High-90.94% Beta1.24
Dividend %- Quick Ratio2.00 Sales past 5Y- Gross Margin- 52W Low8.46% ATR0.24
Employees4 Current Ratio2.00 Sales Q/Q- Oper. Margin- RSI (14)28.92 Volatility9.38% 15.87%
OptionableNo Debt/Eq- EPS Q/Q48.70% Profit Margin- Rel Volume0.22 Prev Close0.77
ShortableNo LT Debt/Eq- EarningsSep 23 AMC Payout- Avg Volume764.80K Price0.77
Recom- SMA20-44.54% SMA50-46.34% SMA200-76.54% Volume167,155 Change-0.01%
Aug-14-17Downgrade Maxim Group Buy → Hold
Aug-16-19 07:33AM  The Daily Biotech Pulse: Roche Snags Double Nod For Personalized Cancer Drug, Bellicum Offering, Nabriva Braces For Contepo Resubmission Benzinga
Aug-14-19 09:10AM  DelMar Pharmaceuticals Announces Pricing Of $6.8 Million Underwritten Public Offering PR Newswire -40.47%
Aug-13-19 09:00AM  DelMar Pharmaceuticals Reports Updated Results on Twenty Patients from the Phase 2 Clinical Trial of VAL-083 as First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM) PR Newswire -7.08%
Jul-31-19 08:00AM  DelMar Pharmaceuticals Achieves Two-Thirds Enrollment for Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM) PR Newswire +5.95%
Jul-24-19 12:17PM  Here Is What's Driving The Rally In DelMar Pharmaceuticals Benzinga +20.89%
08:30AM  DelMar Pharmaceuticals Enrolls First Patient in the Recently-Approved Adjuvant Setting Arm of Phase 2 Study of VAL-083 for the Treatment of MGMT-Unmethylated Glioblastoma Multiforme PR Newswire
Jul-10-19 05:30AM  DelMar Announces Relocation of Company Headquarters to San Diego PR Newswire
Jun-27-19 07:26AM  The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO Benzinga +7.36%
05:30AM  Delmar Pharmaceuticals Announces Termination Of Rights Offering PR Newswire
Jun-25-19 05:28PM  DelMar Pharmaceuticals Announces Extension Of Rights Offering To July 12, 2019 PR Newswire -8.97%
Jun-11-19 05:30AM  Delmar Pharmaceuticals Updates The Terms Of Previously Announced Rights Offering PR Newswire +5.85%
Jun-05-19 03:10PM  DelMar Pharmaceuticals Announces Closing of Financing PR Newswire
Jun-03-19 08:45AM  DelMar Provides Clinical Update on VAL-083 from Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated Glioblastoma at a Key Opinion Leader Forum during the American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire -49.75%
08:30AM  DelMar Pharmaceuticals Announces $3.6 Million Registered Direct Offering PR Newswire
May-29-19 09:00AM  DelMar Pharmaceuticals Updates Key Dates of Rights Offering PR Newswire -9.34%
May-23-19 02:30PM  DelMar Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE -19.35%
May-20-19 05:30AM  DelMar Pharmaceuticals Announces Expansion of Scientific Advisory Board PR Newswire -11.91%
May-15-19 05:30AM  DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2019 Financial Results PR Newswire -17.54%
May-08-19 08:12AM  DelMar Pharmaceuticals Announces Key Dates and Timeline for Stockholder Participation in Rights Offering PR Newswire -11.73%
May-07-19 04:53PM  DelMar Pharmaceuticals Announces 1-for-10 Reverse Stock Split PR Newswire
Apr-04-19 05:30AM  DelMar Pharmaceuticals Welcomes Dr. John de Groot, Chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Center, as founding member of the Company's Scientific Advisory Board PR Newswire -7.78%
Apr-03-19 05:30AM  DelMar Pharmaceuticals Receives Approval from MD Anderson Cancer Center's IRB for Protocol Expansion to Include Maintenance Stage MGMT-unmethylated GBM Patients in Ongoing Phase 2 Trial of VAL-083 PR Newswire
Feb-20-19 05:30AM  DelMar Pharmaceuticals Achieves Halfway Enrollment Point for Phase 2 Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM PR Newswire -13.62%
Feb-19-19 02:30PM  DelMar Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Feb-12-19 05:30AM  DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2019 Financial Results PR Newswire
Feb-07-19 05:30AM  DelMar Pharmaceuticals Receives Nasdaq Listing Extension PR Newswire
Nov-23-18 07:30AM  Consolidated Research: 2018 Summary Expectations for iKang Healthcare Group, Collectors Universe, QuickLogic, The Ultimate Software Group, Internet Gold Golden Lines, and DelMar Pharmaceuticals Fundamental Analysis, Key Performance Indications GlobeNewswire
Nov-20-18 05:30AM  DelMar Presents Clinical Update on VAL-083 From Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated GBM at The Society for NeuroOncology Annual Meeting PR Newswire
Nov-14-18 05:30AM  DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2019 Financial Results PR Newswire
Oct-26-18 11:25AM  Treat Aurora Cannabis Stock Normally at Your Own Peril InvestorPlace
Oct-16-18 10:06AM  Who Owns Most Of DelMar Pharmaceuticals Inc (NASDAQ:DMPI)? Simply Wall St. +7.76%
Oct-10-18 05:30AM  DelMar Announces Further Validation of the Mechanism of Action of VAL-083 PR Newswire -6.15%
Sep-24-18 06:00AM  DelMar Pharmaceuticals Announces Fiscal Year 2018 Annual Financial Results PR Newswire
Sep-19-18 05:23PM  DelMar Pharmaceuticals Appoints Oppenheimer & Co. Inc. as Strategic Advisor PR Newswire +5.71%
Jun-26-18 06:00AM  DelMar Pharmaceuticals Announces Accelerated Patient Enrollment of Phase 2 Trial in MGMT-unmethylated Recurrent GBM PR Newswire +5.93%
Jun-25-18 06:00AM  DelMar Pharmaceuticals Appoints World-Renowned Molecular Biologist Dr. Napoleone Ferrara to Board of Directors PR Newswire -6.27%
May-30-18 07:50AM  Wired News Keryx Biopharmaceuticals Shares Results of Clinical Trial for Treating Patients with Advanced Chronic Kidney Disease with Ferric Citrate ACCESSWIRE
May-22-18 05:30AM  DelMar Appoints Saiid Zarrabian to Full-Time President and CEO PR Newswire
May-17-18 05:30AM  DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results PR Newswire
Apr-17-18 02:00PM  DelMar Pharmaceuticals Presents Positive Updates on Two Ongoing Clinical Trials with VAL-083 for Treatment of MGMT-unmethylated GBM PR Newswire
Apr-16-18 09:00AM  DelMar Pharmaceuticals Announces Multiple Presentations at Annual Meeting of the American Association for Cancer Research PR Newswire
Feb-28-18 08:20AM  Todays Research Reports on Stocks to Watch: Lipocine and DelMar Pharmaceuticals ACCESSWIRE
Feb-20-18 12:00PM  DelMar Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE -8.49%
Feb-14-18 05:39PM  DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2018 Financial Results PR Newswire
03:19PM  Is DelMar Pharmaceuticals Inc (NASDAQ:DMPI) A Healthcare Industry Laggard Or Leader? Simply Wall St.
Dec-26-17 07:33AM  DelMar Pharmaceuticals' stock rockets after cancer treatment granted 'Fast Track' designation MarketWatch +34.13%
05:30AM  DelMar Pharmaceuticals Announces Fast Track Designation for VAL-083 in Recurrent Glioblastoma PR Newswire
Dec-08-17 01:33PM  Should You Be Concerned About DelMar Pharmaceuticals Incs (DMPI) Shareholders? Simply Wall St.
Nov-30-17 06:25PM  How Should You Think About DelMar Pharmaceuticals Incs (DMPI) Risks? Simply Wall St.
Nov-21-17 03:06PM  DelMar Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at The Society for NeuroOncology Annual Meeting PR Newswire +13.05%
Nov-14-17 10:00AM  DelMar Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Nov-13-17 06:14PM  DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2018 Financial Results PR Newswire
Nov-07-17 04:05PM  DelMar Pharmaceuticals Appoints Saiid Zarrabian as Interim Chief Executive Officer PR Newswire
Oct-31-17 05:30AM  DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Component of Combination Chemotherapy Regimens for the Treatment of Solid Tumors including Brain and Ovarian Cancer PR Newswire
Oct-24-17 12:17PM  ONCLIVE: Novel Alkylating Agent Defies Mechanisms of Resistance in GBM Tumors ACCESSWIRE
Oct-17-17 02:11PM  Is Now The Right Time To Invest In Healthcare And DelMar Pharmaceuticals Inc (DMPI)? Simply Wall St.
Oct-10-17 09:30AM  SeeThruEquity Issues Update on DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) ACCESSWIRE +7.01%
Oct-05-17 07:50AM  Earnings Review and Free Research Report: DelMar Missed Earnings Expectations ACCESSWIRE
Oct-04-17 11:00AM  Investor Network: DelMar Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE
Oct-03-17 05:30AM  DelMar Pharmaceuticals Presents Poster at AACR's Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer PR Newswire
Sep-28-17 06:50PM  DelMar Pharmaceuticals Announces Fiscal Year 2017 Financial Results PR Newswire -6.09%
Sep-27-17 05:30AM  DelMar Pharmaceuticals to Present at AACR Special Conference on Ovarian Cancer PR Newswire
Sep-26-17 10:00AM  CEO Jeffery Bacha Discusses DelMars VOL-083 Clinical Trials and the Major Milestones Ahead GlobeNewswire +9.88%
Sep-22-17 02:20PM  DelMar Pharmaceuticals Announces Closing Of $10 Million Registered Direct Offering Priced At-The-Market PR Newswire -10.18%
Sep-21-17 08:00AM  Today's Research Reports on Trending Tickers: DelMar Pharmaceuticals and Ionis Pharmaceuticals ACCESSWIRE -8.41%
Sep-20-17 03:31PM  DelMar Pharmaceuticals Announces $10 Million Registered Direct Offering Priced At-The-Market PR Newswire
05:30AM  DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083 PR Newswire
Sep-18-17 08:00AM  DelMar Pharmaceuticals Receives IND Allowance from FDA to Initiate Clinical Trials of VAL-083 for the Treatment of Ovarian Cancer PR Newswire
Sep-11-17 04:00AM  DelMar Pharmaceuticals Initiates Phase 2 Clinical Trial in Newly Diagnosed MGMT-unmethylated Glioblastoma Multiforme PR Newswire +6.69%
Sep-06-17 01:58PM  DelMar Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference on September 10-12, 2017 PR Newswire -10.16%
Jul-24-17 08:30AM  DelMar Pharmaceuticals Receives Approval from China's Human Genetic Resources Administration to Initiate Phase 2 Clinical Trial in Newly Diagnosed GBM PR Newswire
Jul-18-17 08:30AM  DelMar Pharmaceuticals Announces Completion of First Site Initiation Visit for STAR-3 Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM PR Newswire
Jul-11-17 08:30AM  DelMar Pharmaceuticals Appoints Saiid Zarrabian to the Board of Directors and Names Dr. Erich Mohr as Chairman PR Newswire
Jun-29-17 08:30AM  DelMar Pharmaceuticals Joins National Brain Tumor Society's Research Roundtable PR Newswire
Jun-22-17 08:30AM  DelMar Pharmaceuticals Receives Institutional Review Board Approval for Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM PR Newswire
Jun-16-17 08:30AM  DelMar Presents Poster of Clinical Research with VAL-083 in Patients with Chemo-resistant Glioblastoma ("GBM") at SNO's Pediatric Neuro-Oncology Basic and Translational Research Conference PR Newswire
May-18-17 05:13PM  DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2017 Financial Results PR Newswire
May-11-17 08:30AM  DelMar Formalizes Collaboration with PRA Health Sciences for Phase 3 Trial of VAL-083 in Recurrent Glioblastoma Multiforme (GBM) PR Newswire
May-08-17 08:30AM  DelMar Presents New Mechanism of Action Data for its Lead Agent VAL-083 in Temozolomide-Resistant Glioblastoma Multiforme (GBM) at the World Federation of Neuro-Oncology Societies (WFNOS) PR Newswire
Apr-27-17 08:30AM  DelMar to Present Poster of Clinical Research with VAL-083 in Patients with Chemo-Resistant Glioblastoma ("GBM") at ASCO Annual Meeting PR Newswire
Apr-25-17 08:30AM  DelMar Pharmaceuticals Collaborates with Duke University to Explore VAL-083 as a Front-Line Treatment for Glioblastoma Multiforme PR Newswire
Apr-21-17 08:30AM  DelMar Pharmaceuticals Announces Closing Of $9,000,000 Public Offering Of Common Stock And Warrants PR Newswire
Apr-13-17 08:16AM  DelMar Pharmaceuticals Announces Pricing Of $9,000,000 Public Offering Of Common Stock And Warrants PR Newswire
Apr-12-17 04:22PM  DelMar Pharmaceuticals Announces Proposed Public Offering Of Common Stock And Warrants PR Newswire
Apr-05-17 08:30AM  DelMar Pharmaceuticals Provides VAL-083 Updates from the Ongoing American Association for Cancer Research (AACR) Annual Meeting PR Newswire
08:30AM  DelMar Pharmaceuticals Provides VAL-083 Updates from the Ongoing American Association for Cancer Research (AACR) Annual Meeting
Mar-28-17 08:30AM  DelMar Pharmaceuticals Announces Abstract Presentations for the American Association for Cancer Research (AACR) Annual Meeting in April 2017 PR Newswire
Mar-02-17 08:30AM  DelMar Pharmaceuticals to Participate in Key Opinion Leader Luncheon on Glioblastoma Multiforme Featuring Dr. James Perry, MD PR Newswire
Feb-28-17 01:00PM  DMPI: Three New Clinical Trials of VAL-083 To be Initiated in 2017 Zacks Small Cap Research
01:00PM  DMPI: Three New Clinical Trials of VAL-083 To be Initiated in 2017
Feb-16-17 01:04PM  DELMAR PHARMACEUTICALS, INC. Financials
Feb-13-17 08:40AM  DelMar Pharmaceuticals Announces Dosing of the First Patient in Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM) PR Newswire
08:15AM  DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2017 Financial Results PR Newswire
Feb-10-17 05:18PM  DELMAR PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
Feb-07-17 01:00PM  DelMar Pharmaceuticals Inc (DMPI) Moves Forward With Flagship Chemotherapy Into Phase II Insider Monkey
01:00PM  DelMar Pharmaceuticals Inc (DMPI) Moves Forward With Flagship Chemotherapy Into Phase II at Insider Monkey
Jan-30-17 09:33AM  DelMar Pharmaceuticals, Inc. - "Optimism and Opportunity as we Initiate Clinical Trials for MGMT-unmethylated GBM Patients at MD Anderson" Accesswire
Jan-25-17 08:30AM  DelMar Pharmaceuticals and MD Anderson Initiate New Phase Two Clinical Trial of VAL-083 for MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM) PR Newswire
Jan-09-17 08:30AM  DelMar Pharmaceuticals Receives Additional Non-Dilutive Funding from the Government of Canada to Support Expanded Research with Lead Product Candidate VAL-083 PR Newswire
Dec-19-16 09:15AM  DelMar Pharmaceuticals, Inc. - "21st Century Cures Act - A Holiday Gift for New Research in the Fight Against Cancer and Other Serious Diseases" Accesswire
DelMar Pharmaceuticals, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a DNA-targeting agent, which is in Phase II clinical study for the treatment of glioblastoma multiforme (GBM), as well as other solid tumors, including ovarian cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China; and Duke University to evaluate VAL-083 as a front-line treatment for newly diagnosed patients with GBM. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Vancouver, Canada.